Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Antibody–drug conjugates in acute myeloid leukemia

Nature Clinical Practice Oncology volume 3, pages 238–239 (2006)Cite this article

boxed-textLarson RA et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442–1452

The approval of gemtuzumab ozogamicin represents a breakthrough in cancer immunotherapy but further study is required to improve efficacy and reduce toxicity and resistance in acute myeloid leukemia

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Taussig DC et al. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086–4092

    Article  CAS  Google Scholar 

  2. Sievers EL et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244–3245

    Article  CAS  Google Scholar 

  3. Linenberger ML et al. (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98: 988–994

    Article  CAS  Google Scholar 

  4. Jurcic JG (2005) Immunotherapy for acute myeloid leukemia. Curr Oncol Rep 7: 339–346

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chairman of Molecular Pharmacology and Chemistry, and P Maslak and JG Jurcic are Associate Members of the Leukemia Service, Department of Medicine, at Memorial Sloan–Kettering Cancer Center, New York, 10021, NY, USA

    David A Scheinberg

  2. Molecular Pharmacology and Chemistry Program, Experimental Therapeutics Center, Leukemia Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY, USA

    David A Scheinberg

Authors
  1. David A Scheinberg
    View author publications

    Search author on:PubMed Google Scholar

  2. Joseph G Jurcic
    View author publications

    Search author on:PubMed Google Scholar

  3. Peter Maslak
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David A Scheinberg.

Ethics declarations

Competing interests

D Scheinberg holds patents in the field of anti-CD33 antibody therapy, although not those included in the reviewed article. Memorial Sloan–Kettering Cancer Center is the owner of these patents.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheinberg, D., Jurcic, J. & Maslak, P. Antibody–drug conjugates in acute myeloid leukemia. Nat Rev Clin Oncol 3, 238–239 (2006). https://doi.org/10.1038/ncponc0478

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc0478

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing